Q3 FY2026
Filed Nov 16, 2026Eloxx starts Phase 2b EXACT study and clears EXPRESS IND; net loss widens to $(5,543) thousand in Q3 2026 with no revenue reported
The release reports clinical progress: first two patients dosed in the Phase 2b EXACT study, IND clearance for the EXPRESS study, and a new Chief Medical Officer. Against that, the net loss and operating expenses rose sharply year over year, no revenue line is reported, and cash fell from $62.0 million at June 30, 2026 to $56.3 million at September 30, 2026. The company states cash is sufficient to fund operations into 2028.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expenses, Q3 2026GAAP | $4.03M | – | – |
| General and administrative expenses, Q3 2026GAAP | $1.93M | – | – |
| Total operating expenses, Q3 2026GAAP | $5.95M | – | – |
| Loss from operations, Q3 2026GAAP | −$5.95M | – | – |
| Other income, net, Q3 2026GAAP | $400K | – | – |
| Net loss, Q3 2026GAAP | −$5.54M | – | – |
| Net loss per share, basic and diluted, Q3 2026GAAP | $(0.49) | – | – |
| Research and development expenses, nine months 2026GAAP | $8.53M | – | – |
| General and administrative expenses, nine months 2026GAAP | $5.67M | – | – |
| Total operating expenses, nine months 2026GAAP | $14.20M | – | – |
| Loss from operations, nine months 2026GAAP | −$14.20M | – | – |
| Other income (expense), net, nine months 2026GAAP | $400 thousand income (presented as (400) thousand in the statement of operations) | – | – |
| Net loss, nine months 2026GAAP | −$13.80M | – | – |
| Net loss per share, basic and diluted, nine months 2026GAAP | $(1.83) | – | – |
| Cash and cash equivalents, September 30, 2026GAAP | $56.3 million ($56,264 thousand) | – | – |
Capital returns
- No share repurchases or dividends are reported in the filing.
- The company effected a one-for-eleven reverse stock split of its common stock in May 2026. All share and per-share amounts in the release reflect the split.
- The authorized shares of common stock were reduced from 500,000,000 to 100,000,000 in connection with the reverse split.
- The release refers to a June 2026 public offering that increased cash balances. The offering size and proceeds are not stated in the document.
What drove it
- Company explanation for R&D: the increase to $4.0 million was primarily related to higher clinical trial expenses associated with the initiation of the Phase 2b EXACT study, as well as increases in personnel costs.
- The company states that Q3 2025 R&D was reduced by a $0.9 million write-off of accounts payable balances with certain vendors under settlement agreements.
- Company explanation for G&A: the increase to $1.9 million was primarily related to higher professional and consulting fees, including legal, audit and tax fees, increased personnel costs, and higher facility and other overhead costs.
- Company explanation for other income, net: the change to $0.4 million of income was primarily related to higher interest income on increased cash balances following the June 2026 public offering and lower interest expense.
- Pipeline progress: first two patients dosed in the Phase 2b EXACT study (NCT07523581) in nonsense mutation Alport syndrome in September 2026.
- Pipeline progress: FDA clearance of the IND for exaluren in nmADPKD announced October 29, 2026, enabling U.S. clinical sites for the Phase 2 EXPRESS study.
- Leadership: T.R. Srinivas, M.D., appointed Senior Vice President and Chief Medical Officer in October 2026. Geno Germano appointed to the Board effective October 19, 2026.
Concerns
- Net loss for Q3 2026 was $(5,543) thousand, compared with $(351) thousand in Q3 2025. Net loss for nine months 2026 was $(13,799) thousand, compared with $(3,951) thousand.
- Total operating expenses for Q3 2026 were $5,953 thousand, compared with $285 thousand in Q3 2025, and nine-month operating expenses were $14,199 thousand, compared with $3,089 thousand.
- Cash and cash equivalents declined from $62.0 million at June 30, 2026 to $56.3 million at September 30, 2026.
- The company states its cash is sufficient to fund operations into 2028, which is shorter than the 52-week EXPRESS data timing of the first half of 2029 and the EXPRESS first patient timing of the third quarter of 2027. The filing does not state whether additional capital will be needed.
- The forward-looking statements section lists the company's need for and ability to obtain additional capital as a risk factor.
- Per-share figures reflect the one-for-eleven reverse stock split, so per-share loss comparisons across periods are affected by the split as stated in the release.
What to watch
- Topline data from the 16-week placebo-controlled portion of the Phase 2b EXACT study, expected in mid-2027.
- Final 32-week data from the EXACT study, expected by the end of 2027.
- First patient dosed in the Phase 2 EXPRESS study in nmADPKD, expected in the third quarter of 2027.
- 52-week topline data from EXPRESS, expected in the first half of 2029.
- Whether FDA grants Breakthrough Therapy Designation for exaluren in nmADPKD. The release states any designation would depend on clinical results and further FDA review.
- Cash runway and any future financing, given the company's statement that cash funds operations into 2028.
- Operating expense trend as the EXACT and EXPRESS studies progress, given the Q3 2026 increase in R&D and G&A.
Balance sheet and cash flow
- Cash and cash equivalents: $56,264 thousand at September 30, 2026, compared with $4,785 thousand at December 31, 2025, and $62.0 million at June 30, 2026 as stated in the text.
- Total assets: $58,261 thousand at September 30, 2026, compared with $5,270 thousand at December 31, 2025.
- Total current liabilities: $17,192 thousand at September 30, 2026, compared with $17,177 thousand at December 31, 2025.
- Total stockholders' equity (deficit): $41,069 thousand at September 30, 2026, compared with $(11,907) thousand at December 31, 2025.
- The company believes its cash and cash equivalents will be sufficient to fund its operations into 2028.
- No operating cash flow, investing cash flow, financing cash flow or debt figures are reported in the document.
Analysis
Eloxx reported a clinical-stage third quarter with no revenue line in the document. Total operating expenses rose to $5,953 thousand in Q3 2026 from $285 thousand in Q3 2025, and the net loss widened to $(5,543) thousand from $(351) thousand. The company attributes the R&D increase mainly to clinical trial expenses for the initiation of the Phase 2b EXACT study and to higher personnel costs, and the G&A increase mainly to professional and consulting fees, personnel costs and facility and overhead costs. The Q3 2025 R&D figure was a net credit of $(250) thousand, which the company says was reduced by a $0.9 million vendor settlement write-off, so the year-over-year R&D comparison is distorted by that prior-period item.
For nine months 2026, R&D was $8,528 thousand against $1,158 thousand, and G&A was $5,671 thousand against $1,931 thousand. Net loss for nine months was $(13,799) thousand, or $(1.83) per share, against $(3,951) thousand, or $(9.12) per share. The release states that all per-share amounts reflect the one-for-eleven reverse stock split effected in May 2026, and the weighted average share counts in the statement of operations differ sharply between the periods, so per-share figures should be read with that split in mind.
Other income, net was $0.4 million in Q3 2026 against other expense, net of $0.1 million in Q3 2025. The company attributes the change to higher interest income on cash balances following the June 2026 public offering and lower interest expense. The offering size is not stated in the document.
On the balance sheet, cash and cash equivalents were $56.3 million at September 30, 2026, down from $62.0 million at June 30, 2026 and up from $4,785 thousand at December 31, 2025. Stockholders' equity moved to $41,069 thousand from a deficit of $(11,907) thousand at year-end 2025. The company states cash is sufficient to fund operations into 2028. No operating or financing cash flow figures are printed, so the quarterly cash decline cannot be traced to its components from this document.
Operationally, the quarter's milestones were the first two patients dosed in the Phase 2b EXACT study, FDA IND clearance for exaluren in nmADPKD announced October 29, 2026, the finalized 52-week EXPRESS design targeting about 60 adults, and the appointment of a Chief Medical Officer. No guidance was provided in the release, so no outlook comparison is possible.
Management, verbatim
The third quarter marked important progress for Eloxx, as we dosed the first two patients in our Phase 2b EXACT study in nonsense mutation Alport syndrome. With the EXPRESS protocol finalized and IND clearance in hand, we now have two programs in rare kidney disease,
Sumit Aggarwal, President and Chief Executive Officer
Not in the filing
stated, not guessed- Revenue and collaboration income: the document reports no revenue line. The company describes a licensing arrangement with Almirall for ZKN-013 but does not print any revenue or milestone figure for it.
- Prior-quarter (Q2 2026) operating expense, net loss and EPS figures: not printed in the document, so sequential comparisons are null.
- Year-over-year and sequential percentage changes for all metrics: not printed.
- Cash and cash equivalents at September 30, 2025: not printed. The December 31, 2025 figure is given but is not the same-period prior-year comparison.
- Operating cash flow, investing cash flow, financing cash flow and free cash flow: not printed.
- Size and gross proceeds of the June 2026 public offering: not printed.
- Financial guidance or outlook for 2026 or later financial results: not provided.
- Total debt and any borrowings: not printed.
- Consensus estimates and share price reaction: not provided and not included.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.